No Data
No Data
Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.85) by 24.71 percent. This is a 37.25 percent increase over losses
Inhibikase Therapeutics GAAP EPS of -$3.57 Misses by $0.82, Revenue of $0.26M In-line
Express News | Inhibikase Therapeutics FY23 EPS $(3.57); Cash Position $13.3M As Of Dec. 31
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
04:19 PM EDT, 03/27/2024 (MT Newswires) -- Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
Press Release: Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET BOSTON
Express News | HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price Target
No Data
TrytosaveabitOP : We were pleased with the discussion we had with the FDA as we begin the process of building our first NDA package needed for approval," said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase. "Our bioequivalence studies were presented to the FDA and we were given specific guidance on the manufacturing requirements necessary to complete the NDA. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and we plan to seek all 11 indications for which imatinib mesylate has been approved, including its use in children. There is significant work ahead of us as we discuss these details with potential commercialization partners and carry out the work needed for the NDA submission," noted Dr. Werner.